CHMP in Favor of Sanofi's Aubagio - Analyst Blog

By
A A A

Recently, Sanofi ( SNY ) received some encouraging news with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of its drug, Aubagio (teriflunomide). The company is looking to get Aubagio approved for the treatment of relapsing forms of multiple sclerosis (RMS) in adult patients.

We note that CHMP did not recommend a new active substance (NAS) designation for Aubagio. Sanofi is planning to request a re-examination of CHMP's decision in relation to the NAS designation.

Aubagio is already approved in the US (Sep 2012) as an oral once-daily treatment for patients with RMS and generated US sales of €7 million in the fourth quarter of 2012. We believe that Aubagio possesses significant commercialization opportunity.

Sanofi has another RMS candidate, Lemtrada (alemtuzumab), in its pipeline. The FDA's decision regarding the approval of Lemtrada is expected in the second half of 2013.

We note that competition in the oral multiple sclerosis market is intense. Novartis ' ( NVS ) Gilenya already has a lead in the oral MS market with the product being approved in Sep 2010. Another major competitor could be Biogen Idec 's ( BIIB ) Tecfidera (dimethyl fumarate, formerly BG-12) which is currently under regulatory review in the US and EU. A response from the US Food and Drug Administration (FDA) on the approval of Tecfidera is expected shortly.  

Sanofi carries a Zacks Rank #3 (Hold) in the short run, while Merrimack carries a Zacks Rank #4 (Sell). Right now, Novo Nordisk ( NVO ) looks more attractive in the pharma space with a Zacks Rank #2 (Buy).



BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BIIB , CHMP , NVO , NVS , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

Most Active by Volume

7,404,375
  • $17.01 ▼ 0.23%
7,078,524
  • $13.67 ▼ 3.66%
6,566,355
  • $14.67 ▼ 0.81%
5,327,955
  • $10 ▲ 0.60%
5,291,466
  • $12.05 ▼ 0.08%
5,194,969
  • $98.04 ▼ 0.76%
4,971,666
  • $3.41 ▲ 4.92%
4,585,168
  • $25.2415 ▼ 1.48%
As of 10/1/2014, 09:49 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com